The accelerating pace of technological and analytical development in the fields of genetic and phenotypic profiling has ushered in an era of great promise for multiple sclerosis (MS) research. As we continue to identify modest but meaningful associations to MS susceptibility, disease course, treatment response, and other clinical or paraclinical phenotypes, we must begin to (1) embark on the challenging set of studies that will integrate disparate observations into clinical algorithms, and (2) validate their clinical utility. Genetic data are receiving much of the attention today, but they are unlikely to be sufficient to offer a personalized approach to disease management in MS. Rather, the genetic architecture of the disease, once uncovered, will offer a fixed platform upon which more dynamic molecular profiles can be assembled to deconstruct the structure of the patient population that we label with a diagnosis of MS. The tools and methods to gain insight into the heterogeneity of MS patients are available today; we must now realize their potential in enhancing the care of MS patients.
International MS Genetics Consortium. (2008 ) Refining genetic associations in multiple sclerosis. Lancet Neurol7: 567-569.
2.
Aulchenko, Y.S., Hoppenbrouwers, I.A., Ramagopalan, S.V., Broer, L., Jafari, N., Hillert, J. et al. (2008) Genetic variation in the KIF1b locus influences susceptibility to multiple sclerosis. Nat Genet40: 1402-1403.
3.
Baechler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ortmann, W.A., Espe, K.J. et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA100: 2610-2615.
4.
Baranzini, S.E., Wang, J., Gibson, R.A., Galwey, N., Naegelin, Y., Barkhof, F. et al. (2009) Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet18: 767-778.
5.
Barcellos, L.F., Sawcer, S., Ramsay, P.P., Baranzini, S.E., Thomson, G., Briggs, F. et al. (2006) Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet15: 2813-2824.
6.
Breij, E.C., Brink, B.P., Veerhuis, R., Van Den Berg, C., Vloet, R., Yan, R. et al. (2008) Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol63: 16-25.
7.
Byun, E., Caillier, S.J., Montalban, X., Villoslada, P., Fernandez, O., Brassat, D. et al. (2008) Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol65: 337-344.
8.
Caillier, S.J., Briggs, F., Cree, B.A., Baranzini, S.E., Fernandez-Vina, M., Ramsay, P.P. et al. (2008) Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol181: 5473-5480.
9.
Comabella, M., Craig, D.W., Camina-Tato, M., Morcillo, C., Lopez, C., Navarro, A. et al. (2008) Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS ONE3: e3490.
10.
Compston, A. and Coles, A. ( 2008) Multiple sclerosis. Lancet372: 1502-1517.
11.
Corvol, J.C., Pelletier, D., Henry, R.G., Caillier, S.J., Wang, J., Pappas, D. et al. (2008) Abrogation of T cell quiescence characterizes patients at high risk for multiple sclerosis after the initial neurological event. Proc Natl Acad Sci USA105: 11839-11844.
12.
De Jager, P.L., Jia, X., Wang, J., de Bakker, P.I.W., Ottoboni, L., Aggarwal, N.T. et al. (2009) Analysis of genome scans and replication identify CD6. ICSBP1, and TNFRSF1a as novel multiple sclerosis susceptibility loci . Nature Genetics. (in press).
13.
De Jager, P.L., Rossin, E., Pyne, S., Tamayo, P., Ottoboni, L., Viglietta, V. et al. (2008) Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain131: 1701-1711.
14.
Deluca, G.C., Ramagopalan, S.V., Herrera, B.M., Dyment, D.A., Lincoln, M.R., Montpetit, A. et al. (2007) An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci USA104: 20896-20901.
15.
Ekegren, T., Hanrieder, J. and Bergquist, J. ( 2008) Clinical perspectives of high-resolution mass spectrometry-based proteomics in neuroscience: exemplified in amyotrophic lateral sclerosis biomarker discovery research. J Mass Spectrom43: 559-571.
16.
Fusco, C., Andreone, V., Coppola, G., Luongo, V., Guerini, F., Pace, E. et al. (2001) Hla-Drb1*1501 and response to copolymer-1 therapy in relapsing-remitting multiple sclerosis. Neurology57: 1976-1979.
17.
Gage, B.F., Eby, C., Johnson, J.A., Deych, E., Rieder, M.J., Ridker, P.M. et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther84: 326-331.
18.
Greenberg, S.A., Pinkus, J.L., Pinkus, G.S., Burleson, T., Sanoudou, D., Tawil, R. et al. (2005) Interferonalpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol57: 664-678.
19.
Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J., De Jager, P.L. et al. (2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med357: 851-862.
20.
Jacob, A., Weinshenker, B.G., Violich, I., Mclinskey, N., Krupp, L., Fox, R.J. et al. (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol65: 1443-1448.
21.
Lucchinetti, C., Bruck, W., Parisi, J., Scheithauer, B., Rodriguez, M. and Lassmann, H. ( 2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol47: 707-717.
22.
Matiello, M., Lennon, V.A., Jacob, A., Pittock, S.J., Lucchinetti, C.F., Wingerchuk, D.M. et al. (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology70: 2197-2200.
23.
McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P., Lublin, F.D. et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol50: 121-127.
24.
McLaughlin, K.A. and Wucherpfennig, K.W. ( 2008) B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol98: 121-149.
25.
Miller, A., Avidan, N., Tzunz-Henig, N., Glass-Marmor, L., Lejbkowicz, I., Pinter, R.Y. et al. (2008) Translation towards personalized medicine in multiple sclerosis. J Neurol Sci274: 68-75.
26.
Nelson, M.R., Bacanu, S.A., Mosteller, M., Li, L., Bowman, C.E., Roses, A.D. et al. (2009) Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J9: 23-33.
27.
O’Connor, K.C., McLaughlin, K.A., De Jager, P.L., Chitnis, T., Bettelli, E., Xu, C. et al. (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med13: 211-217.
28.
Okuda, D.T., Srinivasan, R., Oksenberg, J.R., Goodin, D.S., Baranzini, S.E., Beheshtian, A. et al. (2009) Genotype-phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures . Brain132: 250-259.
29.
Quintana, F.J., Farez, M.F., Viglietta, V., Iglesias, A.H., Merbl, Y., Izquierdo, G. et al. (2008) Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA105: 18889-18894.
30.
Racke, M.K. ( 2008) The role of B Cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol21(Suppl. 1): S9-S18.
31.
Rinaldi, L., Gallo, P., Calabrese, M., Ranzato, F., Luise, D., Colavito, D. et al. (2006) Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients. Brain129: 1993-2007.
32.
Roxburgh, R.H., Seaman, S.R., Masterman, T., Hensiek, A.E., Sawcer, S.J., Vukusic, S. et al. (2005) Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology64: 1144-1151.
33.
Steinman, L. ( 2008) New targets for treatment of multiple sclerosis. J Neurol Sci274: 1-4.
34.
Van Baarsen, L.G., Van Der Pouw Kraan, T.C., Kragt, J.J., Baggen, J.M., Rustenburg, F., Hooper, T. et al. (2006) A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun7: 522-531.
35.
Van Der Pouw Kraan, T.C., Wijbrandts, C.A., Van Baarsen, L.G., Voskuyl, A.E., Rustenburg, F., Baggen, J.M. et al. (2007) Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann Rheum Dis66: 1008-1014.
Yang, C.H., Yu, C.J., Shih, J.Y., Chang, Y.C., Hu, F.C., Tsai, M.C. et al. (2008) Specific EGFR mutations predict treatment outcome of stage IIIb/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol26: 2745-2753.
38.
Zivadinov, R., Uxa, L., Bratina, A., Bosco, A., Srinivasaraghavan, B., Minagar, A. et al. (2007) HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on mri in patients with multiple sclerosis. Int Rev Neurobiol79: 521-535.
